Novartis AG's ( VTX:NOVN ) earnings announcement last week was disappointing for investors, despite the decent ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Novartis has agreed to pay Monte Rosa $150 million upfront ... Jefferies London Healthcare Conference (London, UK) – November 19, 2024. A webcast of the fireside chat will be accessible via the ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

Evidence suggests that combining metformin with standard of care could increase survival and offer other benefits to patients with high-volume disease.

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

MTM chairperson Dr Tom McCarthy said the company had a strong track record of biotech company creation in the UK, and will ...

MTM chairperson Dr Tom McCarthy said the company had a strong track record of biotech company creation in the UK, and will ...

PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is ...